Rationale and Design of “Can Very Low Dose Rivaroxaban (VLDR) in Addition to Dual Antiplatelet Therapy Improve Thrombotic Status in Acute Coronary Syndrome (VaLiDate-R)” Study
Journal of Thrombosis and Thrombolysis - Netherlands
doi 10.1007/s11239-019-02014-5
Full Text
Open PDFAbstract
Available in full text
Date
December 23, 2019
Authors
Publisher
Springer Science and Business Media LLC